Generics Bulletin Originals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
What’s Next? Five Things To Look Out For In April
Generics Bulletin previews the most noteworthy and anticipated events for April 2024.
Leading The Charge On US Humira Competition, Organon Sets Out Strategy
With US biosimilar competition to Humira slow to start in 2023, Organon’s US biosimilars head Jon Martin talks about how the firm is pushing forward to ramp up progress on adalimumab this year, as well as longer-term opportunities.
Alvotech Sees Opportunities Open Up With US Approvals
With long-awaited US approvals now rolling in and a growing pipeline of future biosimilars, further opportunities are opening up for Alvotech – including potentially launching a second interchangeable Stelara biosimilar in the US just a few months after market formation – chief commercial officer Anil Okay and chief strategy officer Ming Li tell Generics Bulletin.
What’s Next? Five Things To Look Out For In March
Generics Bulletin previews the most noteworthy and anticipated events for March 2024.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
‘A Global Movement For More Democracy In Medicine’ – Formycon Chief Talks Biosimilars Strategy
Characterizing biosimilars as a global movement towards the democratization of medicine, Formycon CEO Stefan Glombitza speaks to Generics Bulletin in detail about the company’s recent deals, launches and key pipeline assets, in the first part of an exclusive two-part interview.
Fixing The UK Market: Government Must Move From ‘Transactional’ To ‘Strategic’ Approach
With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.
Leading The Charge On US Humira Competition, Organon Sets Out Strategy
With US biosimilar competition to Humira slow to start in 2023, Organon’s US biosimilars head Jon Martin talks about how the firm is pushing forward to ramp up progress on adalimumab this year, as well as longer-term opportunities.
Vardenafil Vaults To The Top Of UK Price Rises In March
Price increases from multiple suppliers pushed vardenafil to the top of our Biggest Risers table for March 2024.
Multiple UK Generics See Triple-Digit Rises In February
A raft of different generics saw their average UK trade price more than double in February 2024, according to the latest figures from market researcher WaveData.
Azithromycin Leads Off UK Rises In January
Azithromycin topped our rundown of the steepest UK generic trade price rises in January 2024, based on figures from WaveData.
Riluzole Prices Skyrocket As UK Shortages Bite
One of the sharpest UK generic price increases seen for years occurred in December, with riluzole 50mg tablets suddenly becoming more than 20 times more expensive than in the previous month, amid shortages of the motor neurone diseases treatment.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.